
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Screening and Surveillance for Gastric Cancer in the United States</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "‚ñ∂";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on Screening and Surveillance for Gastric Cancer in the United States</strong></summary>
            <div>
                <ul><li>- <b>Source:</b> AGA Clinical Practice Update Expert Review</li><li>- <b>Journal:</b> Gastroenterology</li><li>- <b>Publication:</b> February 2025;168:405‚Äì416</li></ul>
                
        <details>
            <summary><strong>üí° Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended minimum number of biopsies for suspected gastric atrophy/IM, and how should they be collected?</li><li>- What percentage of lesions diagnosed as low-grade dysplasia (LGD) on biopsy are up-staged after endoscopic resection?</li><li>- For a patient with nonvisible indefinite/low-grade dysplasia (IND/LGD) on index endoscopy, when should a repeat high-quality endoscopy be performed?</li><li>- What is the size cutoff for Type I gastric carcinoids that prompts referral for surgical resection due to metastasis risk?</li><li>- H. pylori eradication reduces GC incidence by what percentage according to a meta-analysis of RCTs?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üö® Rationale for GC Screening in the U.S.</strong></summary>
            <div>
                <ul><li>- Gastric Cancer (GC) is a leading cause of preventable cancer death in certain US populations.</li><li>- The focus is on intestinal-type noncardia gastric adenocarcinoma, primarily related to chronic <b>H. pylori</b> infection.</li></ul>
                
        <details>
            <summary><strong>U.S. Statistics & Disparities</strong></summary>
            <div>
                <ul><li>- Estimated <b>26,500</b> new cases and <b>11,130</b> deaths in 2023.</li><li>- Dismal 5-year survival rate of <q><b>32%</b></q>, as <q><u><25%</u></q> are diagnosed at an early, curable stage.</li><li>- Noncardia GC disproportionately affects racial/ethnic minorities, immigrants, and underserved populations.</li></ul>
                
        <details>
            <summary><strong>Comparison with Screening Programs (Japan/South Korea)</strong></summary>
            <div>
                <ul><li>- In countries with screening, <q><b>>60-70%</b></q> of GCs are diagnosed early.</li><li>- Survival rates are <q><b>>70%</b></q> overall and <q><b>95-99%</b></q> for early-stage GC.</li><li>- A meta-analysis showed early-stage GCs were more common in screened (<b>73%</b>) vs. non-screened (<b>43%</b>) groups.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Demographic Trends</strong></summary>
            <div>
                <ul><li>- By 2065, immigrants and their descendants will account for <q><u>nearly 90%</u></q> of US population growth.</li><li>- Immigrants from high-incidence regions (Asia, Latin America) retain their elevated GC risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üéØ Identifying High-Risk Individuals for Screening</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 1</u>: Identifiable high-risk groups in the US should be considered for GC screening.</li><li>- A personalized risk assessment is crucial; universal age-based screening is <u>not</u> cost-effective.</li></ul>
                
        <details>
            <summary><strong>Key Risk Factors (See Table 1)</strong></summary>
            <div>
                <ul><li>- <b>First-generation immigrants</b> from high-incidence regions (GC incidence <q><u>‚â•10‚Äì12 per 100,000</u></q>).</li><li>- Regions include: <b>Eastern Europe, Andean Latin America, East Asia</b>.</li><li>- <b>Family history</b> of GC in a first-degree relative.</li><li>- Certain <b>hereditary syndromes</b> (e.g., FAP, Lynch syndrome).</li></ul>
                
        <details>
            <summary><strong>Racial & Ethnic Groups</strong></summary>
            <div>
                <ul><li>- Non-White groups have a <q><b>2- to >10-fold</b></q> higher noncardia GC incidence.</li><li>- Korean Americans ‚â•50 years old have up to <q><b>14.5-fold</b></q> higher risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Socioeconomic & Behavioral Factors</strong></summary>
            <div>
                <ul><li>- Living in areas of <b>persistent poverty</b> (GC mortality is <q><b>43% higher</b></q>).</li><li>- History of chronic <b>H. pylori</b> infection plus:</li><li>- - Smoking history (<q><u>>20 pack-years</u></q>).</li><li>- - Diet high in salt, red/processed meats.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recommended Screening Age</strong></summary>
            <div>
                <ul><li>- Optimal age to initiate screening is unclear, but <q><b>age 45</b></q> is suggested.</li><li>- - Aligns with CRC screening age for combined procedures.</li><li>- For family history, start <q><u>10 years earlier</u></q> than the youngest affected relative.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ü©∫ Primary Screening Modality: Endoscopy</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 2</u>: Endoscopy is the <b>best test</b> for screening and surveillance.</li><li>- It allows direct visualization, mucosal staging, and biopsies for risk stratification.</li></ul>
                
        <details>
            <summary><strong>Elements of High-Quality Endoscopy</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 3</u>: A high-quality exam is critical for detection.</li><li>- The endoscopic miss rate for early GC is consistently around <q><b>10%</b></q>.</li></ul>
                
        <details>
            <summary><strong>Technical Requirements</strong></summary>
            <div>
                <ul><li>- Use a <b>high-definition white-light</b> system.</li><li>- Employ <b>image enhancement</b> (e.g., NBI, LCI).</li><li>- Ensure adequate <b>gastric mucosal cleansing</b> and insufflation.</li><li>- Allow for adequate visual inspection time and photodocumentation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Effectiveness & Justification</strong></summary>
            <div>
                <ul><li>- A meta-analysis (10 Asian studies) showed endoscopic screening was associated with a <q><b>42% reduction</b></q> in GC mortality.</li><li>- Cost-effectiveness analyses support adding EGD to screening colonoscopy in high-risk US groups (Asian, Hispanic, Black Americans).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ü¶† H. pylori Eradication: Adjunctive Prevention</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 4</u>: H. pylori eradication is an <b>essential adjunct</b> to endoscopic screening.</li><li>- H. pylori is responsible for <q><b>90%</b></q> of the global GC burden.</li></ul>
                
        <details>
            <summary><strong>Evidence for Eradication</strong></summary>
            <div>
                <ul><li>- Meta-analysis of non-US RCTs showed eradication leads to:</li><li>- - <q><b>46%</b></q> reduction in GC incidence (NNT = <q>72</q>).</li><li>- - <q><b>39%</b></q> reduction in GC mortality (NNT = <q>135</q>).</li><li>- Benefit is greatest <u>before</u> development of precancerous changes (atrophy/metaplasia).</li></ul>
                
        <details>
            <summary><strong>Impact on Pre-existing Lesions</strong></summary>
            <div>
                <ul><li>- A non-US RCT with 27-year follow-up found:</li><li>- - Eradication in patients <u>without</u> baseline precancerous changes ---> <q><b>63%</b></q> GC risk reduction.</li><li>- - Eradication in patients overall ---> <q><b>43%</b></q> GC risk reduction.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Screening & Treatment Strategy</strong></summary>
            <div>
                <ul><li>- Consider <b>opportunistic screening</b> (non-serologic tests) in high-risk individuals.</li><li>- Consider <b>familial-based testing</b> (screening adult household members).</li><li>- - Family-based approach has a <q><u>3-fold higher</u></q> eradication success rate and <q><u>70% lower</u></q> recurrence rate.</li><li>- Confirm eradication in all patients at least <q><b>4 weeks</b></q> after treatment.</li></ul>
                
        <details>
            <summary><strong>Optimal Age for H. pylori Screening</strong></summary>
            <div>
                <ul><li>- Not established for the US population.</li><li>- Taipei Global Consensus suggests screening between ages <q><b>20 and 40</b></q> for primary prevention.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>- Eradication is <u>not a stand-alone strategy</u>.</li><li>- Individuals with existing advanced histologic changes (GIM, atrophy) remain at risk and require endoscopic surveillance.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üî¨ Endoscopic & Histologic Management</strong></summary>
            <div>
                <ul><li>- A systematic approach is needed to detect, biopsy, and report premalignant conditions.</li></ul>
                
        <details>
            <summary><strong>Biopsy Protocol for Staging</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 5</u>: Use a systematic protocol (e.g., <b>updated Sydney System</b>) for suspected atrophy/metaplasia.</li></ul>
                
        <details>
            <summary><strong>Procedure</strong></summary>
            <div>
                <ul><li>- Obtain a minimum of <q><b>5 total biopsies</b></q>.</li><li>- Place samples from <b>antrum/incisura</b> and <b>corpus</b> in separately labeled jars.</li><li>- Biopsy any suspicious areas separately.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Improving Detection</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 6</u>: GIM and dysplasia are endoscopically detectable but often missed in the US due to lack of familiarity.</li><li>- Image-enhancing technologies (NBI, LCI) can detect GIM with sensitivity/specificity <q><b>>85-90%</b></q> without magnification.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathology Reporting Consensus</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 7</u>: Endoscopists and pathologists should agree on consistent reporting for atrophic gastritis/metaplasia.</li></ul>
                
        <details>
            <summary><strong>Minimum Required Documentation</strong></summary>
            <div>
                <ul><li>- Presence/absence of <b>H. pylori</b>.</li><li>- Severity of <b>atrophy</b> and/or <b>metaplasia</b>.</li><li>- Histologic <b>subtyping of GIM</b> (e.g., incomplete vs. complete), if applicable.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üó∫Ô∏è Post-Screening Management Pathway (See Figure 1)</strong></summary>
            <div>
                <ul><li>- Management is determined by the findings of the index screening endoscopy.</li></ul>
                
        <details>
            <summary><strong>Normal Mucosa (No Atrophy, GIM, or Neoplasia)</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 8</u>: The decision to continue screening depends on individual risk factors and patient preference.</li><li>- Consider ongoing screening for those with a <b>strong family history</b> or multiple risk factors.</li><li>- Optimal interval is not well-defined, but consider every <q><b>3-5 years</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Atrophic Gastritis (AG) / Gastric Intestinal Metaplasia (GIM)</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 9</u>: All individuals with confirmed AG/GIM require risk stratification.</li></ul>
                
        <details>
            <summary><strong>High-Risk Features Warranting Surveillance</strong></summary>
            <div>
                <ul><li>- <b>Severe</b> atrophic gastritis.</li><li>- <b>Multifocal</b> or <b>incomplete-type</b> GIM.</li><li>- <b>Corpus-extended</b> GIM.</li><li>- Other risk factors (e.g., family history).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Interval</strong></summary>
            <div>
                <ul><li>- Consider endoscopic surveillance every <q><b>3 years</b></q>.</li><li>- Shorter intervals may be needed for multiple risk factors or severe, extensive GIM.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dysplasia & Early Gastric Cancer (EGC)</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 10 & 11</u>: Management requires expertise and often referral.</li></ul>
                
        <details>
            <summary><strong>Indefinite (IND) & Low-Grade Dysplasia (LGD)</strong></summary>
            <div>
                <ul><li>- All dysplasia diagnoses should be confirmed by an <b>experienced GI pathologist</b>.</li><li>- - Approx. <q><b>40%</b></q> of IND cases are reclassified on expert review.</li><li>- Eradicate H. pylori to reduce inflammation and improve diagnostic accuracy.</li><li>- Refer patient to a center with expertise in gastric neoplasia.</li></ul>
                
        <details>
            <summary><strong>Follow-up for Non-Visible Dysplasia</strong></summary>
            <div>
                <ul><li>- After H. pylori eradication, perform a repeat high-quality EGD with IEE by an experienced endoscopist.</li><li>- For non-visible IND/LGD, repeat EGD within <q><b>6 months</b></q>.</li><li>- If dysplasia persists as non-visible, repeat EGD in <q><b>6-12 months</b></q> (LGD) or <q><b>12 months</b></q> (IND).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>High-Grade Dysplasia (HGD) & EGC</strong></summary>
            <div>
                <ul><li>- Refer to an expert for <b>Endoscopic Submucosal Dissection (ESD)</b> with the goal of en bloc, R0 resection.</li><li>- H. pylori eradication is essential but should <u>not delay</u> intervention.</li></ul>
                
        <details>
            <summary><strong>Follow-up for Non-Visible HGD</strong></summary>
            <div>
                <ul><li>- A 'second-look' endoscopy should be done <q><b>as soon as possible</b></q> due to high risk of synchronous cancer.</li><li>- If still non-visible, repeat EGD with biopsies in <q><b>3 months</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk of Upstaging</strong></summary>
            <div>
                <ul><li>- For visible dysplasia, endoscopic resection is both diagnostic and therapeutic.</li><li>- A meta-analysis showed that after resection, nearly <q><b>25%</b></q> of lesions with LGD on biopsy were up-staged:</li><li>- - <q><b>17%</b></q> to HGD.</li><li>- - <q><b>7%</b></q> to carcinoma.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance After Neoplasia Resection</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 12</u>: All patients with resected gastric neoplasia require ongoing endoscopic surveillance.</li><li>- Surveillance should be continued <b>indefinitely</b> for resected HGD or GC.</li><li>- Intervals depend on lesion histology and resection completeness (R0 status).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üè® Special Conditions & Considerations</strong></summary>
            <div>
                <ul><li>- Management of specific findings and patient populations.</li></ul>
                
        <details>
            <summary><strong>Type I Gastric Carcinoids (gNETs)</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 13</u>: These are typically indolent tumors found in the setting of atrophic gastritis.</li><li>- Account for <q><b>70-80%</b></q> of all gNETs.</li></ul>
                
        <details>
            <summary><strong>Management by Size</strong></summary>
            <div>
                <ul><li>- <b><1 cm:</b> May consider resection.</li><li>- <b>1‚Äì2 cm:</b> <u>Should</u> be endoscopically resected.</li><li>- <b>>2 cm:</b> High risk of metastasis. Refer for <b>cross-sectional imaging</b> and <b>surgical resection</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>De-escalation of Screening & Surveillance</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 14</u>: Screening and surveillance should only be performed on individuals fit for endoscopic or surgical treatment.</li><li>- Stop when a person is no longer a candidate for intervention due to comorbidities or preference.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation & Health Equity</strong></summary>
            <div>
                <ul><li>- <u>Best Practice Advice 15</u>: A personalized approach is needed to address disparities.</li><li>- Address modifiable risk factors (H. pylori, poverty, diet, tobacco) that disproportionately affect high-risk groups.</li></ul>
                
        <details>
            <summary><strong>Pillars for a Successful Program (See Figure 2)</strong></summary>
            <div>
                <ul><li>- <b>Pre-procedural:</b> Identify high-risk individuals, ensure access and insurance coverage.</li><li>- <b>Intra-procedural:</b> Ensure high-quality endoscopy and ESD proficiency.</li><li>- <b>Post-procedural:</b> Equitable access to surveillance and oncologic care.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
